Fig. 8.

The therapeutic effect of RM-MC-LIP on SCI, and the anti-pyroptosis mechanism. (A) H&E staining of spinal cords of each treatment group (scale bar: 50 µm); (B) The BMS scores of SCI mice treated with minocycline, PEG-MC-LIP and RM-MC-LIP, respectively, healthy mice were utilized as Control (BMS score = 9). **P < 0.005 vs. PEG-MC-LIP group, ###P < 0.001 vs. Saline group. Data were presented as mean ± SD (n = 10); (C) BMS scores of mice at day 49 post-injury; (D) Body weight change of mice (n = 10); (E) The expression of GSDMD-N, GSDMD-E, Caspase-1, ACS and NLRP3 were measured using western blot. β-action as the control; (F) The levels of IL-1β and IL-18 production in the injured spinal cord after the end of treatment was measured by ELISA (n = 6, **P< 0.005, ***P< 0.001).